Background: Fluid refractory septic shock can develop into a hypodynamic cardiovascular state in both children and adults. Despite management of these patients with empirical inotropic therapy (with or without a vasodilator), mortality remains high.
S eptic shock is the leading cause of death in medical intensive care units (1) and is typically characterized as a hyperdynamic, high cardiac output (CO), low systemic vascular resistance state. However, data suggest that as many as one fourth of adult patients had relatively low COs after fluid resuscitation (2, 3) . In addi-tion, children with fluid refractory septic shock are even more likely than adults to have a hypodynamic cardiovascular profile. After fluid resuscitation, up to 58% of pediatric patients with septic shock have cardiac indices Ͻ3.3 L/min/m 2 (4) . Notably, children with this hypodynamic septic shock phenotype had a mortality rate that was almost three times higher than their hyperdynamic counterparts. Likewise, mortality in adults with this hemodynamic pattern is high, exceeding 50% (2, 3) . Inotropes (dopamine, epinephrine), inodilators (dobutamine, milrinone), and vasodilators (nitroprusside, nitroglycerin) are commonly used in cardiogenic shock and occasionally used in the setting of hypodynamic septic shock (4) . However, these therapeutic interventions have potential risks and have not been validated in clinical trials.
The intra-aortic balloon counterpulsation (IABC) cardiac assist device is presently approved by the United States Food and Drug Administration for use in various forms of shock including septic shock (5) . The first IABC device was tested in animal experiments in the 1950s (6, 7) . In 1967, Kantrowitz et al. (8) used IABC in three patients with cardiogenic shock. This study (8) and two other clinical series (9, 10) had limited success on outcome but interest grew due to the dem-onstrated beneficial hemodynamic effects. A surgically placed counterpulsation device with the ability to inflate and deflate in synchronization with cardiac function was available for clinical studies by the 1970s (11) . The septic shock indication was largely based on preclinical and clinical studies conducted at that time. In large animals challenged with Gramnegative bacteria, IABC improved survival times and hemodynamics and had variable effects on organ injury (12) (13) (14) in contrast to no effect observed in a model using endotoxin infusion over a short time period (15) . Clinically, several open label case series supported the use of IABC during sepsis in the setting of severe coronary disease or evidence of a low output state (16 -19) .
Despite the approval of IABC for septic shock, the well-established associated risks (limb ischemia, bleeding, vascular injury, renal injury, and infection) and difficulty of placement largely precluded the clinical adoption of this approach (20 -22) . However, the development of a bedside percutaneously inserted device has made the procedure easier and has led to the widespread use of IABC for several cardiac indications (23, 24) . The last two decades have seen further technical advances including smaller sheaths and advanced computer software programs that have improved synchronization and augmentation (25) . The technologically advanced IABC device with a better risk/benefit ratio and simplified operation has not been studied in clinical septic shock.
The purpose of the present investigation was to test the efficacy of the current generation of the IABC device in a large animal model of septic shock and to determine whether clinical studies including randomized, controlled trials are warranted. Mechanically ventilated dogs were challenged intrabronchially with Staphylococcus aureus to induce pneumonia, bacteremia, and septic shock. After bacterial challenge, the animals were randomized to receive IABC or no pump (controls) for a 68-hr period. Since the risk/benefit ratio of IABC may vary depending on the risk of death, bacterial doses were escalated over the course of the study to increase mortality. All animals received conventional hemodynamic and pulmonary support based on treatment algorithms similar to those used in the routine clinical care of critically ill septic patients (26) . The effect of IABC on survival, cardiac performance, organ injury, and vasopressor dependence was measured.
MATERIALS AND METHODS
Study Design. The experiments described below were performed as part of an approved protocol by the Animal Care and Use Committee of the Clinical Center at the National Institutes of Health. For 11 consecutive weeks, three purpose-bred beagles (12-28 mo, 10 -12 kg) were challenged intrabronchially with S. aureus (n ϭ 33) and followed-up for 96 hrs. Each week, two of the animals were assigned to IABC from 4 to 72 hrs or to no pump (control). The third animal studied each week was assigned to receive whichever therapy the other two animals were not randomized to that week. We gave progressively larger doses of bacteria (4 -8 ϫ 10 9 colony-forming units [cfu]/kg) to increase mortality rates (i.e., risk of death) as weeks progressed. This allowed us to test initially whether the balloon pump was safe using relatively nonlethal challenges (low risk of death); the low mortality bacterial dose would favor the detection of IABC-associated harm. Later in the study, high lethality (high risk of death) challenges were used to enhance our ability to detect benefit. Each week, general anesthesia (propofol, isoflurane) with mechanical ventilation via an endotracheal tube was used both to perform a tracheostomy and to place percutaneous femoral arterial, external jugular venous, and urinary bladder catheters. After tracheostomy, the dogs received continuous sedation (fentanyl, midazolam, and medetomidine) and were maintained with mechanical ventilation, fluids, and vasopressors. Baseline blood cultures and routine blood samples were taken for analysis. A bronchoscope was then used at time 0 to place S. aureus in the lower lobe of the right lung. During the first 4 hrs after S. aureus challenge while sepsis was developing, maintenance fluids (2 mL/kg/hr) and phenylephrine titrated to mean arterial pressure (MAP) Ͼ80 mm Hg were administered. Phenylephrine was used to counteract the hypotensive effects related to sedation while sepsis was developing. After 4 hrs, when symptoms of sepsis were fully developed (based on prior experience with the model), vasopressor support was terminated, intravascular hemodynamics were measured, an echocardiogram was obtained, and blood samples were taken. Treatment for sepsis was then initiated and, similar to human care, was individualized to the hemodynamic, oxygenation, and ventilation needs of each dog. Specifically, the level of fluid, vasopressor, and ventilatory support was dictated by algorithms and adjusted based on transcutaneous oxygen saturation, MAP, pulmonary arterial occlusion pressure (PAOP) determinations, and arterial blood gas monitoring. In addition to the start of standard sepsis treatment, at 4 hrs the dogs were also randomized for treatment with IABC or no pump (control). In those randomized to IABC, balloon counterpulsation was initiated and continued for 68 hrs or until death. The above hemodynamic and blood measurements were repeated at 8 hrs, and on days 1, 2, 3, and 4. Antibiotics (ceftriaxone, 50 mg/kg intravenously [IV] every 24 hr) were started 4 hrs after bacterial inoculation and administered daily through day 4. Animals alive at 96 hrs were considered survivors. Nonsurvivors progressed to terminal shock and death despite the application of fluids and vasopressors per protocol. Veterinarians unaware of the hypothesis being tested could euthanize an animal at any time if they felt it necessary. This did not occur, because the titration of sedatives and narcotics based on a set protocol kept animals pain free.
Surgical Procedures. Animals were fasted for 18 hrs before surgery. After IV induction with propofol (4 -6 mg/kg), tracheal intubation (Rusch, 6F, Duluth, GA), and mechanical ventilation (Fabius Trio, Drager Medical, Telford, PA), anesthesia was maintained with isoflurane (0.5%-1.5%). During surgery animals received 500 mL of normal saline over 30 mins in addition to maintenance fluids (2 mL/kg/hr) until the end of the procedure. A tracheostomy was performed and a tracheostomy tube was placed and secured.
Catheter Placement. Femoral arterial and external jugular venous catheters (Maxxim Medical, Athens, TX) were placed percutaneously using aseptic technique. A 7F pulmonary artery thermodilution catheter (Abbott Critical Care, Chicago, IL) was introduced through an 8F introducer via the external jugular vein into the pulmonary artery. A 20gauge arterial catheter was placed into right femoral artery. An 8F sheath was placed in the left femoral artery for placement of IABC device. A urinary catheter (Cook, Foley 8F, 55 cm, Spencer, IN) was also placed in the bladder aseptically and connected to a bag.
Intra-aortic Balloon and Pump. At 4 hr, fluoroscopy was used to place the tip of the intra-aortic balloon (8F, 9 mL; Datascope Corp., Fairfield, NJ) in the descending thoracic aorta, just distal to the left subclavian artery and then secured in place. The catheter was connected to the console (98XT, Datascope Corp.) of the IABC device and balloon counterpulsation (1:1 augmentation) was initiated. Balloon counterpulsation was optimized by appropriately timing the inflationdeflation cycle of the balloon with the electrocardiogram or arterial blood pressure tracings to maximize diastolic augmentation (the maximum pressure in the proximal aorta during balloon inflation in diastole) while appropriately decreasing assisted systolic and end-diastolic pressures (27) . Controls received an intra-arterial 8F sheath without an IABC device. At 72 hr, IABC was terminated over the course of 1 hr and the balloon catheter was removed.
Bacterial Inoculation. Under general anesthesia (see above), the dogs received preoxygenation with 100% oxygen for 5 mins, the tracheal tube was removed and a sterile bronchoscope (Olympus BF 1T20, Center Valley, PA) was advanced via the tracheal stoma under direct vision into a right lower lobe segmental bronchus (28) . A pulmonary artery flotation catheter was advanced via the suction port of the bronchoscope and wedged with the balloon inflated into a subsegmental bronchus. Ten milliliters of a solution with a known amount of S. aureus bacteria (4 -8 ϫ 10 9 cfu/kg) was administered via the catheter into the right lower lobe. The balloon was deflated and the bronchoscope and pulmonary artery flotation catheter were removed. Preparation of the bacteria has been previously described (29, 30) .
Mechanical Ventilation. The ventilator (Servovent 300, Siemans Medical, Solna, Sweden) was initially set with an FIO 2 25%, positive end-expiratory pressure (PEEP) 5 cm H 2 O, tidal volume 15 mL/kg, and respiratory rate 15 breaths/min. These tidal volumes are standard in intensive care units treating critically ill septic canines (31) (32) (33) . If the oxygen saturation fell below 92%, the FIO 2 was increased to 50%, 75%, and 100% alternating with increases in PEEP, initially increased by five followed by 2 cm H 2 O to reach oxygen saturation Ն92%. The maximum settings were FIO 2 100% and PEEP 12 cm H 2 O. Support was reduced if the oxygen saturation was above 93% for 6 hrs by similar decrements. Blood gas determinations (every 2 hrs until every 8 hrs and every 8 hrs thereafter) were used to set breath rates on the mechanical ventilator. Breath rate was increased by increments of five to maintain PCO 2 under 35 mm Hg or decreased by five if pH Ͼ7. 35 and PCO 2 Յ30 mm Hg. The maximum setting was 35 and the minimum was 15 breaths/min.
Fluids and Vasopressors. During the first 4 hrs after bacterial inoculation before the development of signs and symptoms of sepsis in this model, a phenylephrine infusion (10 mg/ 250 mL, titrated to effect) was used to maintain the animal's blood pressure at a mean of 80 mm Hg (low normal for dogs). This was to insure that sedation did not cause hypotension in any animal while sepsis was developing. During this time, maintenance IV fluid infusion of normosol-M with 27 mEq KCl added (2 mL/kg/hr) was administered. This is a standard maintenance fluid in critically ill septic shock canines in intensive care units (31, 32; B. Hansen, personal communication, 2005) . Four hours after bacterial inoculation T4 h, the phenylephrine was turned off for a washout period of 10 mins.
At T4 h, to simulate hemodynamic support practiced clinically during sepsis, if PAOP was Ͻ10 mm Hg, a fluid challenge (20 mL/kg) was given. If after three fluid challenges, the MAP was Ͻ80 mm Hg, an infusion of norepinephrine was initiated. Norepinephrine was adjusted incrementally (0, 0.2, 0.6, 1.0, and 2.0 g/kg/min) to maintain MAP between 80 and 100 mm Hg. At subsequent time points (every 2 hrs until T12 hr and every 4 hrs thereafter) until the end of the study, if PAOP was Ͻ10 mm Hg, an additional IV fluid challenge (20 mL/kg) was administered. If one averages all the fluids given, including for CO measurements, carriers needed to infuse intravenous medications, i.e., sedation, antibiotics, etc., and all fluid challenges and maintenance fluid given over the 96 hrs of experiments, on average each septic animal received 2.5-3.5 L of crystalloid or the equivalent of approximately 18 -25 L of fluid in a 70 kg (4.5-6.3 L/day) septic human.
Other Intensive Care Unit Therapies. Other care was instituted based on the standard veterinary practices for critically ill dogs requiring sustained mechanical ventilation in the clinical setting (31, 32) . Every 4 hrs, the animal's mouth was flushed with chlorhexidine solution and the eyes were lubricated with a sterile petroleum gel (33) . The forelimbs were placed square with the slightly elevated head and the hind limbs were serially rotated between left and right positions. Passive limb movements (fore and hind limbs) were performed every 4 hrs. Every 12 hrs, sterile saline (3 mL) was instilled in the trachea followed by tracheal suctioning. The inner cannula of the tracheostomy was cleaned with chlorhexidine and then rinsed with sterile saline two times each day or more frequently if secretions accumulated. All dressings of catheter sites were changed daily. Throughout the study, a heated water blanket and regular blankets were used to maintain core temperature between 36.5°C and 37.5°C. Humidity in the tubing was maintained using a humidifier (Conchatherm III, Hudson RCI-AB) attached to the airway system. To protect the dogs from stress-induced stomach ulcers, famotidine, an H 2 blocker (1 mg/kg IV every 12 hr), was administered and to protect from venous thrombosis during mechanical ventilation and sedation, heparin (3000 IU intramuscularly every 8 hrs) was administered until the end of the study.
Sedation Management. The adequacy of sedation was evaluated and adjusted by a clinician or trained technician continuously at the bedside for 96 hrs after initiation of midazolam (0.2 mg/kg loading dose, 50 g/kg/min infusion) and fentanyl (5 g/kg loading dose, 0.7 g/kg/min infusion). Both the fentanyl and midazolam infusions were increased in increments of one fourth of the dose, every 5 mins until adequate sedation had been obtained. Medetomidine infusion (2-5 g/kg/ min) was used to supplement sedation as needed according to set criteria. Criteria for adequacy of sedation were continuously monitored as follows: 1) the animal should be breathing comfortably in synchrony with the ventilator with jaw tone present but 3) the animal should be unresponsive to light tactile stimuli. Criteria for reducing sedation were also monitored and included the following: 1) palpebral reflexes not present; and 2) the animal not responsive to painful stimuli (toe squeeze). Physiologic Measurements. CO, mean pulmonary artery pressure, PAOP, and central venous pressure were determined via a pulmonary artery thermodilution catheter placed in the external jugular vein. MAP was measured and heart rate was calculated via the femoral arterial pressure recording. Left ventricular ejection fraction was determined by ultrasound (Sonos 5500, Philips Medical). The CO was standardized to the animal's weight in kilograms (cardiac index). These measurements were performed at baseline, 4, 24, 48, 72, and 96 hrs after intrabronchial bacterial inoculation.
Laboratory Data. Arterial and mixed venous blood gases were measured every 2 hrs until every 8 hrs and every 8 hrs thereafter with a blood gas system (ABL 500; Radiometer, Copenhagen, Denmark). Complete blood counts (STK-S; Coulter Electronics, Hialeah, FL) and chemistries were performed with an automatic analyzer at 24 hrs and every 24 hrs thereafter. Blood (isolator tubes) was also obtained for quantitative blood cultures at 24 hrs and every 24 hrs thereafter.
Statistical Methods. Survival times were analyzed using a Cox proportional hazards model (34) with dose of bacteria identified as low (first 6 weeks of study) and high (last 5 weeks of study) based on control (no pump) mortality. As each week of the study had both IABC and no pump animals, the effect of IABC during low-and high-lethality challenges were estimated controlling for study week. Survival time differences between IABC and no pump animals were presented as an odds ratio reflecting the beneficial (or harmful) mortality effects of treatment compared with control. Hemodynamic, laboratory, and measures of pulmonary and cardiac support data were analyzed using a four-way analysis of variance procedure (35) . The four factors in the analysis of variance model included lethality (low and high), group (IABC vs. control), dog nested within group, and time. Interactions among lethality, group, and time were included in the model. Interactions between dog and all other factors formed the error term. Time was treated as a continuous variable, so that the group-time interaction tested for differences among slopes, and as a class variable to compute an area under the curve to summarize the complete time course of the study.
RESULTS

Survival, Organ Injury, and Treatment Differences with Low Versus High
Bacterial Challenges. There were no sig-nificant differences in baseline hemodynamic measurements and blood chemistries except for a lower serum creatinine, arterial PO 2 and pH, and higher plateau pressure in control animals challenged with high compared with low doses of bacteria (all p Ͻ 0.05) ( Table 1) . Although statistically significant, these differences were small and of uncertain physiologic relevance. In control animals (no pump), mortality rates increased from 17% to 86% during the first 6 weeks of the study compared with the last 5 weeks (bacterial doses of 4 -7 vs. 8.0 ϫ 10 9 cfu/kg) with a significant decrease in survival time in animals receiving the highest dose of bacteria. Compared with control animals receiving the lower bacterial doses, controls receiving the highest dose required significantly greater mechanical ventilatory support including higher FIO 2 concentrations (p ϭ 0.0003) and higher PEEP levels (p ϭ 0.04) to maintain similar oxygen saturation goals (Ն92%) and PaO 2 levels (Fig. 1A, B , and E). Set breath rates on mechanical ventilation rates were not significantly different (data not shown) comparing control animals receiving high-and low-bacterial dose. These breath rates maintained comparable arterial pH and PaCO 2 levels in highand low-bacterial dose control animals (all p ϭ not significant; Fig. 1D and F) . In controls, plateau pressures were significantly greater in animals receiving high vs. low doses of bacteria (p Ͻ 0.0009), but on average, always Ͻ30 cm H 2 O (Fig.  1C) , and therefore not indicative of a need to institute lower tidal volumes (36) . Furthermore, control animals receiving the highest bacterial dose required higher norepinephrine doses (p ϭ 0.0001), but a similar volume of cumulative fluid intake (p ϭ 0.6) and number of fluid challenges (p ϭ 0.34) ( Fig. 2A-C) to maintain comparable MAP (Ϸ80 mm Hg) and PAOP goals (8 -10 mm Hg) and central venous pressure levels ( Fig. 2D-F) . Indicators of organ injury such as (A Ϫ a)O 2 gradient (p ϭ 0.0005), left ventricular ejection fraction (p ϭ 0.08), liver function test [alanine transferase (p ϭ 0.03), lactic dehydrogenase (p ϭ 0.04)], and serum creatinine levels (p ϭ 0.03) were significantly worse with the highest vs. lowest doses of bacteria ( Fig. 3A-E) . Lactate levels fell similarly throughout the 96 hrs experiment with low vs. high dose of bacteria (p ϭ not significant; Fig.  3F ).
Effects of IABC on Mortality. IABC did not improve overall mortality rates (con-trols 17% vs. IABC 33%) or survival time among animals challenged with the lower doses of bacteria (1-6 weeks) (Fig. 4A) . In animals receiving the highest dose of bacteria (7-11 weeks), IABC did not improve overall mortality rates (controls 86% vs. IABC 75%), but did improve survival time (23.4 Ϯ 10 hrs longer). In each of the last 5 weeks of the study with the highest dose of bacteria, of the three animals studied, a control always died first (Fig.  4B) . In 3 of these 5 weeks, two IABC animals, despite receiving the same dose of bacteria as the control, survived longer and in 1 week the IABC animal survived longer than the two controls. Only in 1 of these 5 weeks did one control animal survive longer than an IABC animal (Fig.  4B ). During these weeks using the highest bacterial challenge, IABC significantly increased the hazard ratio of survival time compared with controls (p ϭ 0.003; Fig. 5 ). In addition, IABC with highlethality bacterial challenges had a greater beneficial effect on survival time than during the low-lethality challenges (p Ͻ 0.05 for interaction; Fig. 5 ).
Differences in Outcome Other Than Survival With IABC: High-Versus Low-Lethality Challenges. Compared with controls, animals receiving IABC had significantly lower norepinephrine requirements and significantly lower systemic vascular resistance indices with high, but not lowbacterial dose challenges (Fig. 6A , p ϭ 0.002 for interaction; Fig. 6C , p Ͻ 0.0001 for interaction). Despite these lower norepinephrine requirements and systemic vascular resistance indices, there were no significant differences compared with controls in cardiac index (p ϭ 0.34, interaction; Fig. 6B ), mixed venous oxygen saturation, PVO 2 (p ϭ 0.47, interaction; Fig. 6D ), MAP (p ϭ 0.72, interaction; data not shown), or PAOP (p ϭ 0.38, interaction; data not shown) in high-vs. low-dose bacterial challenges. Compared with controls, IABC was associated with a trend toward a greater increase in serum creatinine (p ϭ 0.12, interaction) and a significantly greater increase in blood urea nitrogen (p ϭ 0.002, interaction) with high-compared with lowdose bacterial challenges (Fig. 7) . There was no effect of IABC on liver function tests at high-or low-dose bacterial challenges (data not shown).
Other Laboratory Measurements. There were no significant differences in complete blood counts or electrolytes that could explain the effects of IABC on survival times, norepinephrine doses, or organ injury (Table 2 ).
DISCUSSION
We tested the effect of IABC therapy on outcome after S. aureus intrabron-chial challenge. As expected, animals challenged with high doses of S. aureus had higher mortality rates, and worse cardiopulmonary, renal and hepatic function compared with low-lethal bacterial doses. Likewise, animals challenged with high doses of bacteria required increased amounts of vasopressors, FIO 2 , and PEEP to maintain normal blood pressures and oxygenation levels. IABC therapy increased survival times, decreased vasopressor dose requirements, and lowered the systemic vascular resistance index in animals that had been challenged with high doses of bacteria. Despite lower vasopressor doses and systemic vascular resistance index in these animals, cardiac index and Pv O 2 were similar in the IABC and control groups. During low-lethality challenges (17% mortality), IABC had no significant beneficial effects on vasopressor dose or outcome.
In a severe pneumonia model with depressed cardiac function, optimal fluid management is complex. Excessive fluid may raise cardiac filling pressures to the point of markedly worsening oxygen- ation, whereas inadequate fluid may fail to optimize cardiac preload and impair organ perfusion. These 10-kg animals on average received 2.5-3.5 L of crystalloids over the 96-hr experiment. Giving an equivalent volume of fluid to a 70-kg pa-tient with sepsis would require 18 -25 L of crystalloid resuscitation over 4 days (4.5-6.3 L/day). Indications that fluid resuscitation in our study was sufficient include the facts that lactate levels fell throughout the experiment (Fig. 3F ) and, at least with the highest doses of bacteria (associated with a survival time benefit for IABC), systemic vascular resistance index never rose ( fig. 6C ) and Pv O 2 did not fall (Fig. 6D) . Conversely, cardiac filling pressures were within an acceptable range for fluid resuscitation throughout the experiment (central venous pressure 4 -10 mm Hg and PAOP 10 -12 mm Hg; Fig. 2E , F) suggesting that this volume of fluid was not excessive and therefore did not inappropriately worsen the degree of respiratory failure. Finally, plateau pressures (Fig. 1C) were on average always Ͻ30 cm H 2 O throughout the experiment, within a clinically acceptable range that does not mandate reductions in tidal volume (36) . Thus, there is no clinical evidence to suggest that preload was inadequate, or that cardiac filling pressures or airway pressure were too high in our study.
After high-dose bacterial challenges, renal function as measured by increases in blood urea nitrogen and creatinine worsened during IABC. We initially positioned the IABC catheter tip under fluoroscopy and then sutured the insertion site to hold the tip in place. It is possible that with changing the animal's position every 4 hrs, the catheter migrated, and the balloon potentially intermittently obstructed renal artery flow. However, this effect of IABC on renal function was greater in high-compared with low-dose bacterial challenge. This suggests that catheter migration is not the sole explanation for IABC-induced renal dysfunction, which would have been expected to be similar between low-and high-dose bacterial challenges. We speculate that the IABC may worsen renal blood flow during sepsis through a deflation-induced steal mechanism that may not be fully balanced by the salutary effects of IABC on cardiac performance. This phenomenon could also be a problem in septic humans.
It is also of concern that the IABC was only beneficial on survival times but not rates, and only with high but not with low-dose bacterial challenges. Of note in this study, the balloon pump was neither applied nor discontinued based on therapeutic indications. All animals were randomized for treatment at 4 hrs after bacterial challenge and received IABC independent of severity of cardiac abnormalities or vasopressor needs for 72 hrs Figure 6 . At high-dose bacterial challenges, the IABC compared with no pump caused a trend toward a greater rise in creatinine (p ϭ 0.12, interaction) and a significantly greater rise in blood urea nitrogen (p ϭ 0.002, interaction) over the 68-hr study compared with low-dose bacterial challenges. or until death, whether or not a clinical indication for continuing was still present. It is unknown whether or not IABC would have a more marked beneficial effect if only animals with the most severe cardiovascular abnormalities were randomized and IABC was continued until sufficient recovery of cardiovascular function. Finally, in animals exposed to low-dose bacterial challenges with minimal cardiovascular abnormalities, the ability of the IABC to improve cardiac function and thereby outcome would be expected to be reduced and consistent with this, we found no benefit to IABC therapy in this group.
In our study, cardiac index was always below baseline despite adequate preload, suggesting therapies that enhance cardiac performance without increasing myocardial demand might be beneficial. Dobutamine and sodium nitroprusside are sometimes used in patients with low CO septic shock, to improve cardiac performance. However, neither of these agents has been tested in randomized controlled trials for this indication and their efficacy is uncertain. Dobutamine itself can cause hypotension and arrhythmias, and at high doses it has been associated with worsening outcome during septic shock (37) . Sodium nitroprusside can cause life-threatening hypotension and in renal failure, a common complication of septic shock, toxic metabolites accumulate (38) . Another approach for low CO septic shock is to switch from norepinephrine to epinephrine. However, in canine sepsis, epinephrine compared with other vasopressors has been associated with delayed cardiac recovery (28) and worsened survival (39) . The risks associated with the use of these vasoactive agents during septic shock may, in part, be why the mortality for low CO septic shock remains so high (3). Thus, new therapeutic options for low CO septic shock such as IABC therapy need to be considered.
The mechanism for improved survival times and reduced vasopressor requirements with IABC therapy in severe septic shock is unknown. High-dose vasopressors have been shown to maldistribute blood flow (40) and in similar sepsis models worsen outcome (39) . IABC reduces cardiac workload by decreasing afterload improving left ventricular ejection and outflow. This increase in ventricular outflow on a beat-to-beat basis over time increases MAP, thus lowering vasopressor requirements. In this study with highdose bacterial challenge, as norepinephrine doses decreased in IABC animals, systemic vascular resistance index was lowered and cardiac index was maintained and by 72 hrs mixed venous oxygen saturation, and cardiac index was improved compared with control animals (Fig. 6A-D) . In addition, by inflating at the dicrotic notch, IABC augments diastolic pressure resulting in an increase in coronary perfusion. The decrease in afterload (balloon deflation at end diastole) and increase in coronary perfusion (diastolic augmentation) by IABC is in contrast to vasopressors that increase coronary flow at the expense of reducing cardiac performance. The ability of the IABC to improve cardiac function and reduce vasopressor dependence, thereby decreasing its deleterious effects on cardiac performance and the microcirculation may have improved survival time.
The question remains, have we provided adequate evidence to support IABC studies in septic humans. At low-bacterial doses and less-severe sepsis, we found no significant harmful effects of IABC. However, the number of animals studied was small. As risk of death from infection increased, IABC therapy improved two outcomes that may be related, i.e., longer survival times and lower vasopressor requirements. Animal models are not proof that a therapy will or will not be beneficial in humans. Accordingly, this animal study should not be used to justify use of IABC clinically in septic patients. Moreover, we found no beneficial effect of IABC on survival rates. Nonetheless, clinical septic shock still has an unacceptably high mortality rate (30%-50%) and new therapies are needed (1). In the setting of highly lethal septic shock resulting in a low or normal CO and dependence on high-dose vasopressors, our data suggest that IABC therapy should be further investigated.
This study used a persistent sepsis model that was never used before to study IABC therapy in the treatment of sepsis. The IABC device was in place over 4 days and easily managed by clinicians and technicians without obvious technical problems. The animals were individually treated over days based on standardized algorithms and therapies commonly used in human septic shock. Although there were only 30 IABC-days in these critically ill septic animals, there was no evidence of complications related to catheter placement, limb ischemia, bleeding, infection, or vascular injury. The data in this model with a modern IABC device were consistent with previous studies in animals using older IABC devices showing survival benefits (12, 13, 15 ) and human sepsis studies showing improvement in low CO states (16, 17) .
CONCLUSIONS
In summary, with high-risk, high-dose S. aureus pneumonia-induced septic shock, we found that IABC therapy improved survival time and decreased vasopressor requirements. The modern IABC device has never been formally tested in a sepsis trial and the decrease in renal function demonstrated in our study is concerning. However, in carefully selected patients with low-CO septic shock and a high risk of death, a randomized controlled trial of IABC therapy may be indicated.
